Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol-Reference-Cited by-同舟云学术

Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol

Published:2016-03-26 Issue:5 Volume:21 Page:996-1003
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Tamura Kazuo,Kawai Yasukazu,Kiguchi Toru,Okamoto Masataka,Kaneko Masahiko,Maemondo Makoto,Gemba Kenichi,Fujimaki Katsumichi,Kirito Keita,Goto Tetsuya,Fujisaki Tomoaki,Takeda Kenji,Nakajima Akihiro,Ueda Takanori

Funder

Teijin Pharma Ltd.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

http://link.springer.com/content/pdf/10.1007/s10147-016-0971-3.pdf

Reference10 articles.

1. Coiffier B, Altman A, Pui CH et al (2008) Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 26:2767–2778

2. Cairo MS, Coiffier B, Reiter A et al (2010) TLS Expert Panel. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 149:578–586

3. Jones GL, Will A, Jackson GH et al (2015) Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. Br J Haematol 169:661–671